Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Hikma trims full year revenue forecast on Advair U.S. launch delay

share with twitter share with LinkedIn share with facebook
share via e-mail
05/19/2017 | 09:32am CET

Drugmaker Hikma Pharmaceuticals Plc on Friday lowered its revenue forecast for the full year to reflect a delay in the launch of its generic asthma drug, after U.S. regulators denied approval citing "major" issues with the application.

Shares of the company fell as much 7.47 percent to 1,573 pence, the lowest since May, 2014. They were the top loser on the FTSE 100 bluechip index and the pan-European Stoxx 600 index.

Hikma now expects full-year revenue to be in the range of $2.0 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion (1.7 billion pounds).

Earlier this month, the company said approval for its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair was unlikely in 2017.

Hikma and its partner Vectura Group Plc are in a race with Mylan to launch the first U.S. generic copy of Advair. The FDA has already delayed approval of Mylan's version.

Hikma on Friday lowered its 2017 revenue forecast for its generics business to $670 million, down from its earlier forecast of $800 million.

"This assumes we do not launch our generic version of Advair Diskus in 2017 and reflects the intensifying competitive environment in the U.S.," the company said in a statement.

Hikma maintained its full-year revenue estimate for its injectables unit at a range of $800 million-$825 million, with core operating margin seen in the high 30s.

(Reporting by Sanjeeban Sarkar and Tenzin Pema in Bengaluru; Editing by Sunil Nair)

share with twitter share with LinkedIn share with facebook
share via e-mail
01/19 En route to Davos, Macron makes Versailles the place to be
01/19 GLAXOSMITHKLINE : 19.8% Potential Upside Indicated by Liberum Capital
01/19 GLAXOSMITHKLINE : UK-based drugmaker GlaxoSmithKline mulls Kenya staff cuts
01/19 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc Provides New Data about Comb..
01/19 GLAXOSMITHKLINE : Recent Findings from GlaxoSmithKline plc Has Provided New Info..
01/19 At AstraZeneca, fewer drug projects bring big productivity jump
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
01/15 GLAXOSMITHKLINE : National Institutes of Health - Brian Berridge tapped to manag..
01/13 GLAXOSMITHKLINE : Brian Berridge Tapped to Manage National Toxicology Program
More news
News from SeekingAlpha
05:31a U.S. flu season is getting worse
01/20 STOCKS TO WATCH : Earnings Season Hits Higher Gear
01/18 Big Biopharma in the red in early trade
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 NeuroMetrix inks deal with Glaxo for Quell ex-U.S.; shares ahead 68% premarke..
Financials ( GBP)
Sales 2017 30 076 M
EBIT 2017 8 296 M
Net income 2017 3 592 M
Debt 2017 13 840 M
Yield 2017 5,89%
P/E ratio 2017 19,34
P/E ratio 2018 15,29
EV / Sales 2017 2,70x
EV / Sales 2018 2,66x
Capitalization 67 329 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 31
Average target price 15,5  GBP
Spread / Average Target 15%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132